KalVista Pharmaceuticals Secures Funding to Advance Clinical Programs

KalVista Pharmaceuticals (KALV) has released an update.

KalVista Pharmaceuticals, Inc. has partnered with several underwriters, including Jefferies LLC and Leerink Partners LLC, to sell over 7 million shares and pre-funded warrants, raising around $150.1 million. This capital will mainly support the clinical development of sebetralstat, their leading product candidate, and other preclinical programs. The offering, priced at $15.25 per share, is expected to close by February 20, 2024, bolstering KalVista’s financial position to advance its pharmaceutical endeavors.

For further insights into KALV stock, check out TipRanks’ Stock Analysis page.